Forward Pharma A/S (NASDAQ:FWP) has been given a consensus recommendation of “Buy” by the six ratings firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $24.00.
A number of research analysts have recently issued reports on FWP shares. Jefferies Group LLC set a $22.00 price target on Forward Pharma A/S and gave the company a “hold” rating in a report on Tuesday, April 18th. BidaskClub upgraded Forward Pharma A/S from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. Finally, ValuEngine upgraded Forward Pharma A/S from a “sell” rating to a “hold” rating in a report on Saturday, June 17th.
Forward Pharma A/S (NASDAQ FWP) traded down 0.86% during midday trading on Friday, reaching $24.14. The company’s stock had a trading volume of 24,402 shares. Forward Pharma A/S has a 12-month low of $14.89 and a 12-month high of $33.00.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BlueMountain Capital Management LLC increased its position in shares of Forward Pharma A/S by 15.3% in the second quarter. BlueMountain Capital Management LLC now owns 1,511,043 shares of the biotechnology company’s stock valued at $26,982,000 after buying an additional 200,000 shares during the period. Cowen Inc. acquired a new position in shares of Forward Pharma A/S during the second quarter valued at $225,000. Alliancebernstein L.P. acquired a new position in shares of Forward Pharma A/S during the second quarter valued at $203,000. Alps Advisors Inc. acquired a new position in shares of Forward Pharma A/S during the second quarter valued at $866,000. Finally, Eqis Capital Management Inc. increased its position in shares of Forward Pharma A/S by 25.5% in the second quarter. Eqis Capital Management Inc. now owns 20,178 shares of the biotechnology company’s stock valued at $410,000 after buying an additional 4,097 shares during the period. Hedge funds and other institutional investors own 22.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://stocknewstimes.com/2017/08/16/brokerages-set-forward-pharma-as-fwp-pt-at-24-00.html.
Forward Pharma A/S Company Profile
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
